Skip to main content

Buprenorphine

  • Chapter
  • First Online:
Pain Medicine

Abstract

Sublingual (S/L) buprenorphine is FDA approved only for treatment of opioid addiction (opioid detoxification and maintenance). Buprenorphine in patch form is approved only for analgesia. However, buprenorphine is present at a significantly lower dose in the patch form as compared to the S/L forms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Suggested Reading

  1. Stahl SM. Buprenorphine. In: Stahl’s essential psychopharmacology. New York, NY: Cambridge University Press; 2014. p. 87–90.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert M. Chow MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Chow, R.M., Issa, M. (2017). Buprenorphine. In: Yong, R., Nguyen, M., Nelson, E., Urman, R. (eds) Pain Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-43133-8_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43133-8_39

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43131-4

  • Online ISBN: 978-3-319-43133-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics